{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:52:49Z","timestamp":1782442369352,"version":"3.54.5"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mallinckrodt"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by proximal muscle weakness. H. P. Acthar gel [repository corticotropin injection (RCI)] is a formulation of adrenocorticotropic hormone and has been approved by Food and Drug Administration for use in IIM; however, literature is limited. In this study, we report longitudinal follow-up of myositis patients treated with RCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with refractory IIM who were enrolled in the prospective, open-label RCI trial were included in this study. The post-trial follow-up period was 6\u2009months with assessments every 2\u2009months, which included myositis core set measures including extra-muscular global, muscle and patient global disease activities, HAQ, and manual muscle testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two patients were lost to follow-up after finalization of the trial, and the remaining eight patients were enrolled in the follow-up study. One patient remained on RCI after the trial. In the follow-up period, four of eight patients had flare at on average 4.1\u2009months after the RCI trial. Among the patients who flared, three required an increase in prednisone. One patient was restarted on RCI at 5.5\u2009months, but had minimal improvement after 3\u2009months. Four patients who remained stable continued to satisfy criteria for the definition of improvement through the 6-month follow-up. However, none showed any further improvement in the primary or secondary efficacy outcomes after the initial RCI trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this is the first study reporting the follow-up results of patients treated with standard dose and duration of Acthar. We believe that our study will provide the basis for the development of future randomized RCI trials in IIM.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa076","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T12:16:14Z","timestamp":1580818574000},"page":"2976-2981","source":"Crossref","is-referenced-by-count":9,"title":["Follow-up results of myositis patients treated with H. P. Acthar gel"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-597X","authenticated-orcid":false,"given":"Didem","family":"Saygin","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V","family":"Oddis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Marder","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Formerly North Shore-Long Island Jewish Medical Center, Queens, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Moghadam-Kia","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeya","family":"Nandkumar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Formerly North Shore-Long Island Jewish Medical Center, Queens, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Neiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedin","family":"Dzanko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Koontz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,11]]},"reference":[{"key":"2020092423551290600_keaa076-B1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2020092423551290600_keaa076-B2","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","article-title":"Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis","volume":"46","author":"Getting","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2020092423551290600_keaa076-B3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"ACTH: the forgotten therapy","volume":"27","author":"Montero-Melendez","year":"2015","journal-title":"Semin Immunol"},{"key":"2020092423551290600_keaa076-B4","first-page":"9068061","article-title":"Repository corticotropin injection for treatment of idiopathic inflammatory myopathies","volume":"2016","author":"Patel","year":"2016","journal-title":"Case Rep Rheumatol"},{"key":"2020092423551290600_keaa076-B5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/DDDT.S33110","article-title":"Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series","volume":"6","author":"Levine","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"2020092423551290600_keaa076-B6","doi-asserted-by":"crossref","first-page":"100292","DOI":"10.4172\/2329-6895.1000292","article-title":"H.P. Acthar\u00ae Gel in dermatomyositis and polymyositis treatment registry: an interim analysis","volume":"4","author":"Levine","year":"2016","journal-title":"J Neurol Disord"},{"key":"2020092423551290600_keaa076-B7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","article-title":"Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis","volume":"77","author":"Aggarwal","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020092423551290600_keaa076-B8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020092423551290600_keaa076-B9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2012.09.009","article-title":"ACTH as first line treatment for acute gout in 181 hospitalized patients","volume":"80","author":"Daoussis","year":"2013","journal-title":"Joint Bone Spine"},{"key":"2020092423551290600_keaa076-B10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0961203314532562","article-title":"Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial","volume":"23","author":"Fiechtner","year":"2014","journal-title":"Lupus"},{"key":"2020092423551290600_keaa076-B11","doi-asserted-by":"crossref","first-page":"e000180","DOI":"10.1136\/lupus-2016-000180","article-title":"Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study","volume":"3","author":"Furie","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2020092423551290600_keaa076-B12","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1073\/pnas.0912176107","article-title":"ACTH protects against glucocorticoid-induced osteonecrosis of bone","volume":"107","author":"Zaidi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020092423551290600_keaa076-B13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bone.2005.01.020","article-title":"Multiple melanocortin receptors are expressed in bone cells","volume":"36","author":"Zhong","year":"2005","journal-title":"Bone"},{"key":"2020092423551290600_keaa076-B14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin Sci (Lond)"},{"key":"2020092423551290600_keaa076-B15","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.4049\/jimmunol.161.6.2873","article-title":"Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents","volume":"161","author":"Manna","year":"1998","journal-title":"J Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/10\/2976\/33790276\/keaa076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/10\/2976\/33790276\/keaa076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T06:39:46Z","timestamp":1695710386000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/10\/2976\/5803185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,11]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,3,11]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa076","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,3,11]]}}}